Cue biopharma announces presentations highlighting clinical progress of cue-101, pipeline progress of cue-100 series immuno-stats and immuno-stat data for infectious disease applications at the society for immunotherapy of cancer's (sitc) 35th anniversary annual meeting

Cambridge, mass., nov. 09, 2020 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted t cells within the patient's body, announced today three poster presentations highlighting the company's clinical and pipeline progress at the society for immunotherapy of cancer's 35th anniversary annual meeting (sitc 2020). the posters include a clinical update on cue-101, the lead drug candidate from the il-2 based cue-100 series, and data supporting the potential of the immuno-stat™ (selective targeting and alteration of t cells) platform to selectively engage and modulate targeted t cells within the body in a manner that can address a broad range of indications.
CUE Ratings Summary
CUE Quant Ranking